Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naive Canine Multicentric Lymphoma.

ABSTRACT:

Background

Standard of care treatment for multicentric lymphoma in dogs remains doxorubicin (DOX)-based combination chemotherapy, but owners may hesitate to commit the time and financial resources to complete such a protocol, typically requiring 12-16 visits. Rabacfosadine (RAB), a double prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl) guanine, has substantial single-agent activity in dogs with lymphoma, and a different mechanism of action than DOX.

Hypothesis/objectives

Our objective was to evaluate the efficacy and adverse effect (AE) profile of alternating doses of RAB and DOX in dogs with naïve multicentric lymphoma.

Animals

Fifty-four dogs with previously untreated lymphoma.

Methods

Open-label, multicenter prospective clinical trial. Dogs rec

SUBMITTER: Thamm DH 

PROVIDER: S-EPMC5435064 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature